For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Charles River Laboratories International Inc’s stock clocked out at $174.95, up 2.48% from its previous closing price of $170.72. In other words, the price has increased by $2.48 from its previous closing price. On the day, 1.3 million shares were traded. CRL stock price reached its highest trading level at $177.75 during the session, while it also had its lowest trading level at $172.0.
Ratios:
To gain a deeper understanding of CRL’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 46.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.88. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.83.
On October 02, 2025, Barclays Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $195.
Jefferies Upgraded its Hold to Buy on September 09, 2025, while the target price for the stock was maintained at $195.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Joseph LaPlume bought 400 shares for $152.50 per share.
LaPlume Joseph W sold 800 shares of CRL for $126,080 on Aug 18 ’25. The EVP, Corp Strategy & Develop now owns 24,116 shares after completing the transaction at $157.60 per share. On Aug 18 ’25, another insider, WALLMAN RICHARD F, who serves as the Former Director of the company, bought 22,500 shares for $152.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 8610020352 and an Enterprise Value of 11262431232. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.14 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 2.796 whereas that against EBITDA is 11.785.
Stock Price History:
The Beta on a monthly basis for CRL is 1.51, which has changed by -0.115386546 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $230.02, while it has fallen to a 52-week low of $91.86. The 50-Day Moving Average of the stock is 9.36%, while the 200-Day Moving Average is calculated to be 13.14%.
Shares Statistics:
It appears that CRL traded 924.90K shares on average per day over the past three months and 851110 shares per day over the past ten days. A total of 49.21M shares are outstanding, with a floating share count of 48.66M. Insiders hold about 1.12% of the company’s shares, while institutions hold 102.88% stake in the company. Shares short for CRL as of 1759190400 were 2207028 with a Short Ratio of 2.39, compared to 1756425600 on 2669761. Therefore, it implies a Short% of Shares Outstanding of 2207028 and a Short% of Float of 5.1599998000000005.
Earnings Estimates
Charles River Laboratories International Inc (CRL) is currently under the scrutiny of 13.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $2.38, with high estimates of $2.52 and low estimates of $2.23.
Analysts are recommending an EPS of between $10.48 and $10.0 for the fiscal current year, implying an average EPS of $10.2. EPS for the following year is $10.81, with 16.0 analysts recommending between $11.72 and $10.35.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $990.79M. It ranges from a high estimate of $1.01B to a low estimate of $979M. As of. The current estimate, Charles River Laboratories International Inc’s year-ago sales were $1.01BFor the next quarter, 11 analysts are estimating revenue of $985.56M. There is a high estimate of $1B for the next quarter, whereas the lowest estimate is $974.7M.
A total of 15 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.05B, while the lowest revenue estimate was $3.94B, resulting in an average revenue estimate of $3.99B. In the same quarter a year ago, actual revenue was $4.05BBased on 15 analysts’ estimates, the company’s revenue will be $4.09B in the next fiscal year. The high estimate is $4.17B and the low estimate is $4B.
